Modified branched peptides with a histidine-rich tail enhance in vitro gene transfection.
Successful gene therapy depends on the development of efficient, non-toxic gene delivery systems. To accomplish this objective, our laboratory has focused on solid-phase synthesized peptide carriers, in which the amino acid sequence can be varied precisely to augment intracellular DNA transport. We previously determined that linear and branched co-polymers of histidine and lysine in combination with liposomes enhanced the efficiency of gene transfection. In this study, we have modified two branched histidine-lysine (HK) peptides by adding a histidine-rich tail. In a variety of cell lines, this histidine-rich tail markedly improved transfection efficiency, presumably by increasing the buffering capacity of the polymer. One polymer with a histidine-rich tail, H2K4bT, compared favorably with the commonly used transfection agents. Together with modification of our transfection protocol, these improved HK peptides alone, without liposomes, are the effective carriers of plasmids into a variety of cells. We anticipate that branched HK peptides will continue to be developed as carriers of nucleic acids for in vitro and in vivo applications.
Leng
Qixin
Q
Department of Pathology, University of Maryland Baltimore MSTF Building, 10 South Pine Street, Baltimore, MD 21201, USA.
Mixson
A James
AJ
D000595:Amino Acid Sequence; D001704:Biopolymers / Q000737:chemistry; D045744:Cell Line, Tumor; D002470:Cell Survival; D006639:Histidine / Q000737:chemistry*; D006801:Humans; D008081:Liposomes; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry*; D010957:Plasmids; D014162:Transfection / Q000379:methods*; D001616:beta-Galactosidase / Q000235:genetics
D001704:Biopolymers; C497834:H2K4bT protein; D008081:Liposomes; D010455:Peptides; D006639:Histidine; D001616:beta-Galactosidase
Hum Gene Ther. 1998 May 1;9(7):1037-47
9607415
Bioconjug Chem. 1999 Jan-Feb;10(1):49-55
9893963
Bioconjug Chem. 1999 May-Jun;10(3):406-11
10346871
Nucleic Acids Res. 1999 Sep 1;27(17):3510-7
10446241
Nat Biotechnol. 1999 Sep;17(9):873-7
10471928
Nucleic Acids Res. 2000 Jan 15;28(2):504-12
10606649
Gene Ther. 2000 Jan;7(1):31-4
10680013
Gene Ther. 2000 Oct;7(19):1698-705
11083479
Biochemistry. 1997 Mar 11;36(10):3008-17
9062132
Nucleic Acids Res. 2002 Mar 15;30(6):1338-45
11884631
Biol Pharm Bull. 2002 Jul;25(7):891-7
12132664
Methods Mol Biol. 2004;245:33-52
14707368
Bioconjug Chem. 2004 Jan-Feb;15(1):41-9
14733582
J Gene Med. 2004 Aug;6(8):895-905
15293348
Bioconjug Chem. 1993 Sep-Oct;4(5):372-9
8274523
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301
7638184
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4897-902
8643500
Curr Biol. 1996 Aug 1;6(8):1025-7
8805337
Bioconjug Chem. 1996 Nov-Dec;7(6):703-14
8950489
Hum Gene Ther. 1997 Jan 20;8(2):177-85
9017421
Gene Ther. 1997 Oct;4(10):1100-6
9415317
J Biol Chem. 1997 Jun 13;272(24):15307-12
9182558
Nucleic Acids Res. 2001 Mar 15;29(6):1334-40
11239000